Advertisement

Endocrine

pp 1–7 | Cite as

Effects of dehydroepiandrosterone (DHEA) supplementation on sexual function in premenopausal infertile women

  • Vitaly A. Kushnir
  • Sarah K. Darmon
  • David H. Barad
  • Andrea Weghofer
  • Norbert Gleicher
Original Article
  • 12 Downloads

Abstract

Purpose

To investigate the effects of dehydroepiandrosterone (DHEA) supplementation on female sexual function in premenopausal infertile women of advanced ages.

Methods

This observational study was conducted in an academically affiliated private fertility center. Patients included 87 premenopausal infertile women, 50 of whom completed the study including the Female Sexual Function Index (FSFI) questionnaires and comprehensive endocrine evaluation before and 4–8 weeks after initiating 25 mg of oral micronized DHEA TID.

Results

Age of patients was 41.1 ± 4.2 years, BMI 24.4 ± 6.1 kg/m2, 86% were married, and 42% were parous. Following supplementation with DHEA, all serum androgen levels increased (each P < 0.0001), while FSH levels decreased by 2.6 ± 4.4 from a baseline of 10.3 ± 5.4 mIU/mL (P = 0.009). The FSFI score for the whole study group increased by 7% (from 27.2 ± 6.9 to 29.2 ± 5.6; P = 0.0166). Domain scores for desire increased by 17% (P = 0.0004) and by 12% for arousal (P = 0.0122); lubrication demonstrated an 8% trend towards improvement (P = 0.0551), while no changes in domain scores for orgasm, satisfaction, or pain were observed. Women in the lowest starting FSFI score quartile (<25.7), experienced a 6.1 ± 8.0 (34%) increase in total FSFI score following DHEA supplementation. Among these women, improvements in domain categories were noted for desire (40%), arousal (46%), lubrication (33%), orgasm (54%), satisfaction (24%), and pain (25%).

Conclusions

This uncontrolled observational study implies that supplementation with DHEA improves sexual function in older premenopausal women with low baseline FSFI scores.

Keywords

Female sexual function Infertility Hormone status Androgens Dehydroepiandrosterone (DHEA) 

Notes

Funding

This work was supported by the Foundation for Reproductive Medicine and intramural funds of the Center for Human Reproduction.

Author contributions

V.A.K., D.H.B., and N.G. developed the concept of the study; all authors contributed to data accumulation. S.K.D., A.W., and V.A.K. contributed to data analysis; all authors contributed to data interpretation. V.A.K. wrote the manuscript. All authors contributed to revisions of the manuscript and approved the final submission. V.A.K. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Availability of data and material

Anonymized patient level data are accessible by contacting Mrs. Jolanta Tapper at jtapper@thechr.com.

Compliance with ethical standards

Conflict of interest

N.G. and D.H.B. are co-inventors on several pending and already awarded U.S. patents claiming fertility benefits from androgen supplementation in women with low functional ovarian reserve (LFOR). Both receive royalties from Fertility Nutraceuticals, LLC, in which N.G. also holds shares. Other authors declare that they have no conflict of interest.

Ethics approval

This study received Institutional Review Board (IRB) approval (ER11052015-01) on 11/11/2015 from the IRB of the Center for Human Reproduction. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    M.E. McCool, A. Zuelke, M.A. Theurich, H. Knuettel, C. Ricci, C. Apfelbacher, Prevalence of female sexual dysfunction among premenopausal women: a systematic review and meta-analysis of observational studies. Sex. Med. Rev. 4, 197–212 (2016)CrossRefGoogle Scholar
  2. 2.
    J.M. Weinberger, J. Houman, A.T. Caron, J. Anger, Female sexual dysfunction: a systematic review of outcomes across various treatment modalities. Sex Med Rev. 2018 Feb 3. pii: S2050-0521(18)30001-5.  https://doi.org/10.1016/j.sxmr.2017.12.004
  3. 3.
    H.V. Joffe, C. Chang, C. Sewell, O. Easley, C. Nguyen, S. Dunn, K. Lehrfeld, L. Lee, M.J. Kim, A.F. Slagle, J. Beitz, FDA approval of flibanserin—treating hypoactive sexual desire disorder. N. Engl. J. Med. 374, 101–104 (2016)CrossRefGoogle Scholar
  4. 4.
    R. Basson, J. Berman, A. Burnett, L. Derogatis, D. Ferguson, J. Fourcroy, I. Goldstein, A. Graziottin, J. Heiman, E. Laan, S. Leiblum, H. Padma-Nathan, R. Rosen, K. Segraves, R.T. Segraves, R. Shabsigh, M. Sipski, G. Wagner, B. Whipple, Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol. 163, 888–893 (2000)CrossRefGoogle Scholar
  5. 5.
    A.T. Guay, J. Jacobson, Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J. Sex Marital Ther. 28(Suppl 1), 129–142 (2002)CrossRefGoogle Scholar
  6. 6.
    B. Turna, E. Apaydin, B. Semerci, B. Altay, N. Cikili, O. Nazli, Women with low libido: correlation of decreased androgen levels with female sexual function index. Int. J. Impot. Res. 17, 148–153 (2005)CrossRefGoogle Scholar
  7. 7.
    R.E. Nappi, To be or not to be in sexual desire: the androgen dilemma. Climacteric 18, 672–674 (2015)CrossRefGoogle Scholar
  8. 8.
    R. Worsley, R.J. Bell, P. Gartoulla, S.R. Davis, Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women. J. Sex. Med. 14, 675–686 (2017)CrossRefGoogle Scholar
  9. 9.
    M.M. Kushnir, T. Blamires, A.L. Rockwood, W.L. Roberts, B. Yue, E. Erdogan, A.M. Bunker, A.W. Meikle, Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 56, 1138–1147 (2010)CrossRefGoogle Scholar
  10. 10.
    N. Orentreich, J.L. Brind, R.L. Rizer, J.H. Vogelman, Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59, 551–555 (1984)CrossRefGoogle Scholar
  11. 11.
    N. Gleicher, A. Kim, A. Weghofer, V.A. Kushnir, A. Shohat-Tal, E. Lazzaroni, H.J. Lee, D.H. Barad, Hypoandrogenism in association with diminished functional ovarian reserve. Hum. Reprod. 28, 1084–1091 (2013)CrossRefGoogle Scholar
  12. 12.
    N. Gleicher, V.A. Kushnir, A. Weghofer, D.H. Barad, The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod. Biol. Endocrinol. 14, 23 (2016)CrossRefGoogle Scholar
  13. 13.
    P.J. Robinson, R.J. Bell, M.K. Christakis, S.R. Ivezic, S.R. Davis, Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J. Sex. Med. 14, 1566–1574 (2017)CrossRefGoogle Scholar
  14. 14.
    S.R. Davis, R. Worsley, K.K. Miller, S.J. Parish, N. Santoro, Androgens and female sexual function and dysfunction—findings from the Fourth International Consultation of Sexual Medicine. J. Sex. Med. 13, 168–178 (2016)CrossRefGoogle Scholar
  15. 15.
    M. Khera, Testosterone therapy for female sexual dysfunction. Sex. Med. Rev. 3, 137–144 (2015)CrossRefGoogle Scholar
  16. 16.
    M. Panjari, S.R. Davis, DHEA therapy for women: effect on sexual function and wellbeing. Hum. Reprod. Update 13, 239–248 (2007)CrossRefGoogle Scholar
  17. 17.
    R.F. Spark, Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil. Steril. 77(Suppl 4), S19–S25 (2002)CrossRefGoogle Scholar
  18. 18.
    C.S. Scheffers, S. Armstrong, A.E. Cantineau, C. Farquhar, V. Jordan, Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst. Rev. 1, CD011066 (2015)PubMedGoogle Scholar
  19. 19.
    W. Arlt, F. Callies, J.C. van Vlijmen, I. Koehler, M. Reincke, M. Bidlingmaier, D. Huebler, M. Oettel, M. Ernst, H.M. Schulte, B. Allolio, Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 341, 1013–1020 (1999)CrossRefGoogle Scholar
  20. 20.
    F. Labrie, D.F. Archer, W. Koltun, A. Vachon, D. Young, L. Frenette, D. Portman, M. Montesino, I. Côté, J. Parent, L. Lavoie, A. Beauregard, C. Martel, M. Vaillancourt, J. Balser, É. Moyneur; VVA Prasterone Research Group, Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23, 243–256 (2016)CrossRefGoogle Scholar
  21. 21.
    N. Gleicher, D.H. Barad, Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 9, 67 (2011)CrossRefGoogle Scholar
  22. 22.
    N. Gleicher, A. Kim, A. Weghofer, A. Shohat-Tal, E. Lazzaroni, H.J. Lee, D.H. Barad, Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J. Assist. Reprod. Genet. 30, 49–62 (2013)CrossRefGoogle Scholar
  23. 23.
    N. Gleicher, A. Weghofer, D.H. Barad, Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod. Biomed. Online 21, 360–365 (2010)CrossRefGoogle Scholar
  24. 24.
    D. Barad, H. Brill, N. Gleicher, Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J. Assist. Reprod. Genet. 24, 629–634 (2007)CrossRefGoogle Scholar
  25. 25.
    A. Sen, S.R. Hammes, Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol. Endocrinol. 24, 1393–1403 (2010)CrossRefGoogle Scholar
  26. 26.
    A. Sen, H. Prizant, A. Light, A. Biswas, E. Hayes, H.J. Lee, D. Barad, N. Gleicher, S.R. Hammes, Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc. Natl. Acad. Sci. U.S.A. 111, 3008–3013 (2014)CrossRefGoogle Scholar
  27. 27.
    L.T. Lin, P.H. Wang, S.N. Chen, C.J. Li, Z.H. Wen, J.T. Cheng, K.H. Tsui, Protection of cumulus cells following dehydroepiandrosterone supplementation. Gynecol. Endocrinol. 33, 100–104 (2017)CrossRefGoogle Scholar
  28. 28.
    H. Prizant, N. Gleicher, A. Sen, Androgen actions in the ovary: balance is key. J. Endocrinol. 222, R141–R151 (2014)CrossRefGoogle Scholar
  29. 29.
    C.R. Mendonça, J.T. Arruda, M. Noll, P.M.O. Campoli, W.N.D. Amaral, Sexual dysfunction in infertile women: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 215, 153–163 (2017)CrossRefGoogle Scholar
  30. 30.
    L.S. Millheiser, A.E. Helmer, R.B. Quintero, L.M. Westphal, A.A. Milki, R.B. Lathi, Is infertility a risk factor for female sexual dysfunction? A case-control study. Fertil. Steril. 94, 2022–2025 (2010)CrossRefGoogle Scholar
  31. 31.
    R. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D’Agostino, The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 26, 191–208 (2000)CrossRefGoogle Scholar
  32. 32.
    A. Shohat-Tal, A. Sen, D.H. Barad, V. Kushnir, N. Gleicher, Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nat. Rev. Endocrinol. 11, 429–441 (2015)CrossRefGoogle Scholar
  33. 33.
    N. Gleicher, K. Seier, V.A. Kushnir, A. Weghofer, Y.G. Wu, Q. Wang, D.F. Albertini, D.H. Barad, Associations between peripheral androgens and cortisol in infertile women. J Steroid Biochem Mol Biol. 2016 Apr;158, 82-89CrossRefGoogle Scholar
  34. 34.
    M. Stomati, P. Monteleone, E. Casarosa, B. Quirici, S. Puccetti, F. Bernardi, A.D. Genazzani, L. Rovati, M. Luisi, A.R. Genazzani, Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol. Endocrinol. 14, 342–363 (2000)CrossRefGoogle Scholar
  35. 35.
    J.M. Weinberger, J. Houman, A.T. Caron, D.N. Patel, A.S. Baskin, A.L. Ackerman, K.S. Eilber, J.T. Anger, Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet. Gynecol. 132(2), 453–458 (2018)CrossRefGoogle Scholar
  36. 36.
    J.L. Shifren, B.U. Monz, P.A. Russo, A. Segreti, C.B. Johannes, Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112, 970–978 (2008)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Vitaly A. Kushnir
    • 1
    • 2
  • Sarah K. Darmon
    • 1
  • David H. Barad
    • 1
    • 3
  • Andrea Weghofer
    • 1
    • 4
  • Norbert Gleicher
    • 1
    • 3
    • 4
    • 5
  1. 1.The Center for Human ReproductionNew YorkUSA
  2. 2.Department of Obstetrics and GynecologyWake Forest School of MedicineWinston-SalemUSA
  3. 3.Foundation for Reproductive MedicineNew YorkUSA
  4. 4.Department of Obstetrics and GynecologyMedical University of ViennaViennaAustria
  5. 5.Stem Cell Biology and Molecular Embryology LaboratoryThe Rockefeller UniversityNew YorkUSA

Personalised recommendations